◀ Back to EGFR

CPOX — EGFR

Text-mined interactions from Literome

Gadgeel et al., J Thorac Oncol 2007 (Carcinoma, Non-Small-Cell Lung...) : Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor ( EGFR-TKI ), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor , in patients with platinum refractory non-small cell lung cancer ( NSCLC )
Herrera et al., Rev Recent Clin Trials 2008 (Uterine Cervical Neoplasms) : The evidence supporting the biological rational to combine novel non-cytotoxic agents with CRT is strong, and drugs targeting different molecular pathways are currently under clinical development ( EGFR inhibitors, COX-2 inhibitors , hypoxia targeted agents, etc )
Krishnaswamy et al., Endocrinology 2010 : The EGFR inhibitor AG1478 ( 10 microm ) nearly abolished basal and OT-induced PGF ( 2 alpha ) production and down-regulated COX2 expression and ERK1/2 phosphorylation